Balipodect
(Redirected from TAK-063)
 | |
| Clinical data | |
|---|---|
| Other names | TAK-063; TAK063 |
| Drug class | Phosphodiesterase inhibitor; PDE10A inhibitor; Antipsychotic |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H17FN6O2 |
| Molar mass | 428.427 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Balipodect (INN, USAN; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia.[1][2][3]
It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.[4]
The drug reached phase 2 clinical trials for this indication but its development was discontinued.[1][2] It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.[5][6][7]
See also
[edit]References
[edit]- ^ a b "Balipodect". AdisInsight. 30 January 2018. Retrieved 19 October 2024.
- ^ a b "Delving into the Latest Updates on Balipodect with Synapse". Synapse. 19 September 2024. Retrieved 19 October 2024.
- ^ Suzuki K, Kimura H (July 2018). "TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia". CNS Neuroscience & Therapeutics. 24 (7): 604–614. doi:10.1111/cns.12798. PMC 6489916. PMID 29318783.
- ^ Menniti FS, Chappie TA, Schmidt CJ (2020). "PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?". Frontiers in Neuroscience. 14: 600178. doi:10.3389/fnins.2020.600178. PMC 7855852. PMID 33551724.
- ^ Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Liu W, et al. (2022). "Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules". Frontiers in Pharmacology. 13: 1057083. doi:10.3389/fphar.2022.1057083. PMC 9731127. PMID 36506513.
- ^ Neef J, Palacios DS (September 2021). "Progress in mechanistically novel treatments for schizophrenia". RSC Medicinal Chemistry. 12 (9): 1459–1475. doi:10.1039/d1md00096a. PMC 8459322. PMID 34671731.
- ^ Krogmann A, Peters L, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU (August 2019). "Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities". CNS Spectrums. 24 (S1): 38–69. doi:10.1017/S109285291900124X. PMID 31482779.